Drug Trial Radar · NCT01878617
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
660
Actual
Start
Jun 23, 2013
Primary completion
Oct 13, 2028
Study completion Oct 13, 2031
Sponsor
- Lead sponsor
- St. Jude Children's Research HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Genentech, Inc.; National Cancer Institute (NCI)
- First posted
- Jun 17, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 39 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Historically, medulloblastoma treatment has been determined by the amount of leftover disease present after surgery, also known as clinical risk (standard vs. high risk). Recent studies have shown that medulloblastoma is made up of distinct molecular subgroups which respond differently to treatment. This suggests that clinical risk alone is not adequate to identify actual risk of recurrence. In order to address this, we will stratify medulloblastoma treatment in this phase II clinical trial based on both clinical risk (low, standard, intermediate, or high risk) and molecular subtype (WNT, SHH, or Non-WNT Non-SHH). This stratified clinical and molecular treatment approach will be used to evaluate the following: * To find out if participants with low-risk WNT tumors can be treated with a lower dose of radiation to the brain and spine, and a lower dose of the chemotherapy drug cyclophosphamide while still achieving the same survival rate as past St. Jude studies with fewer side effects. * To find out if adding targeted chemotherapy after standard chemotherapy will benefit participants with SHH positive tumors. * To find out if adding new chemotherapy agents to the standard chemotherapy will improve the outcome for intermediate and high risk Non-WNT Non-SHH tumors. * To define the cure rate for standard risk Non-WNT Non-SHH tumors treated with reduced dose cyclophosphamide and compare this to participants from the past St. Jude study. All participants on this study will have surgery to remove as much of the primary tumor as safely possible, radiation therapy, and chemotherapy. The amount of radiation therapy and type of chemotherapy received will be determined by the participant's treatment stratum. Treatment stratum assignment will be based on the tumor's molecular subgroup assignment and clinical risk. The participant will be assigned to one of three medulloblastoma subgroups determined by analysis of the tumor tissue for tumor biomarkers: * WNT (Strata W): positive for WNT biomarkers * SHH (Strata S): positive for SHH biomarkers * Non-WNT Non-SHH, Failed, or Indeterminate (Strata N): negative for WNT and SHH biomarkers or results are indeterminable Participants will then be assigned to a clinical risk group (low, standard, intermediate, or high) based on assessment of: * How much tumor is left after surgery * If the cancer has spread to other sites outside the brain \[i.e., to the spinal cord or within the fluid surrounding the spinal cord, called cerebrospinal fluid (CSF)\] * The appearance of the tumor cells under the microscope * Whether or not there are chromosomal abnormalities in the tumor, and if present, what type (also called cytogenetics analysis)
Conditions
- Medulloblastoma
Interventions
Craniospinal Irradiation with boost to the primary tumor siteRadiation
All participants will undergo craniospinal irradiation (CSI) with boost to the primary tumor site. The dose given is based on the molecular and risk group as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
CyclophosphamideDrug
Route of Administration (ROA): Intravenously (IV)
CisplatinDrug
ROA: IV
VincristineDrug
ROA: IV
VismodegibDrug
ROA: Orally (PO)
PemetrexedDrug
ROA: IV
GemcitabineDrug
ROA: IV
Aerobic TrainingOther
Neurocognitive RemediationOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival in Stratum W1Time frame: 2 years after diagnosis
- Progression-free Survival in Stratum N1Time frame: 2 years after diagnosis
- Progression-free Survival in Stratum S1 Skeletally Mature CohortTime frame: 2 years after diagnosis
- Change in VO2 Peak ValueTime frame: baseline and 12 weeks post-randomization
- Change in Spatial Span Backward Standard ScoreTime frame: baseline and 10-12 weeks post baseline
Locations
23 sites in 4 countries. Site status is shown where the registry gives one.
Lucille Packard Children's Hospital at Stanford University Medical Center
Palo Alto, California
Rady Children's Hospital
San Diego, California
Yale University
New Haven, Connecticut
Children's National Medical Center
Washington D.C., District of Columbia
University of Florida
Gainesville, Florida
Arnold Palmer Hospital for Children
Orlando, Florida
Children's Hospital and Clinics of Minnesota
Minneapolis, Minnesota
Duke Children's Hospital and Health Center
Durham, North Carolina
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
St. Jude Children's Research Hospital
Memphis, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
Cook Children's Medical Center
Fort Worth, Texas
Texas Children's Cancer Center
Houston, Texas
Sydney Children's Hospital
Randwick, New South Wales, Australia
Children's Hospital at Westmead
Westmead, New South Wales, Australia
Queensland Children's Hospital
Brisbane, Queensland, Australia
Royal Children's Hospital, Melbourne
Melbourne, Victoria, Australia
Perth Children's Hospital
Perth, Western Australia, Australia
Alberta Children's Hospital
Calgary, Alberta, Canada
The Hospital for Sick Children
Toronto, Ontario, Canada
Centre Hospitalier Universitaire Sainte-Justine
Montreal, Quebec, Canada
Starship Children's Hospital
Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.